首页   按字顺浏览 期刊浏览 卷期浏览 Use of Taxol (Paclitaxel) in Breast Cancer
Use of Taxol (Paclitaxel) in Breast Cancer

 

作者: Gabriel N. Hortobagyi,   Frankie A. Holmes,   Richard L. Theriault,   Aman U. Buzdar,  

 

期刊: Oncology  (Karger Available online 1994)
卷期: Volume 51, issue 1  

页码: 29-32

 

ISSN:0030-2414

 

年代: 1994

 

DOI:10.1159/000227413

 

出版商: S. Karger AG

 

关键词: Breast cancer;Chemotherapy;Taxol;Paclitaxel;Doxorubicin

 

数据来源: Karger

 

摘要:

Taxol (paclitaxel) has demonstrated good antitumor activity against metastatic breast cancer (MBC) in phase II trials. The drug is usually well tolerated. However, severe myelosuppression, including rapidly reversible neutropenia, may necessitate dose reductions and may ultimately limit its use as a long-term treatment. Sequential or simultaneous administration of Taxol and doxorubicin may enhance response rates. There appears to be no complete cross-resistance between the two drugs. Current trials are exploring the best way to deliver this combination while keeping dose-limiting toxicity to a minimum. Additionally, single-agent trials are evaluating Taxol in extensively pretreated MBC. The results of these trials are awaited with interest.

 

点击下载:  PDF (1657KB)



返 回